Fluorescence-guided surgery (FGS), which can use tumor-specific antibodies conjugated with fluorescent dyes to visualize primary tumors and metastases, is making progress in preclinical and clinical trials.4,5 In our laboratory, we have demonstrated the usefulness of FGS with an anti-carcinoembryonic antigen (CEA) antibody conjugated to a 650-nm fluorophore in a pancreatic cancer patient-derived orthotopic xenograft (PDOX) model.6 We have also shown the efficacy of a humanized anti-CEA antibody conjugated to an 800-nm fluorescent dye that labels pancreatic cancer in a PDOX mouse model.7 Here, CEACAM3 is linked to pancreatic neoplasm.